Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2020

Transparency Market Research Report Added “Biological Drugs Market (Therapeutic Protein - Levemir, Neulasta, Eylea, Rebif, NovoLog, Enbrel, Avonex, Neupogen, Humalog, Victoza, Lantus, Epogen, Aranesp, and Betaseron; Monoclonal Antibody - Avastin, Rituxan, Lucentis, Humira, Herceptin, and Remicade; Vaccine - Gardasil, Prenvar 13, Fluzone, Cervarix, and Varivax) " to its database.

Global Biological Drugs Market: Snapshot

The global market for biological drugs has been demonstrating an upward movement since the last few years. The rising concerns over the increasing cases of side-effects caused by conventional medicines and drugs are having a positive impact on the demand for biological drugs across the world. The trend is expected to remain so over the forthcoming years with the opportunity in the worldwide biological drugs market expanding at a CAGR of 10.10% during the period from 2014 to 2020 and reaching US 287.1 bn by the end of the forecast period.

Demand for Enbrel to Remain Strong in Future

Lantus, epogen, avonex, victoza, levemir, betaseron, enbrel, humalog, aranesp, neulasta, novolog, neupogen, rebif, and eylea are some of the main therapeutic proteins used in biological drugs. Enbrel has been witnessing a greater demand than other therapeutic proteins, worldwide. Enbrel is used in the treatment of auto-immune diseases, such as juvenile rheumatoid arthritis, plaque, psoriatic, and psoriasis. The growing prevalence of these diseases has influenced the sales of enbrel.

Analysts expect the segment to rise at a CAGR of 14.50% over the forecast period. However, the concerns over side-effects of this protein, such as multiple sclerosis, tuberculosis, allergic reactions, and blood related infections, may limit its demand to some extent in the years to come. Lantus and neulasta are the other important therapeutic proteins, which are likely to gain impetus in the global market over the next few years.

Browse Market Research Report:
http://www.transparencymarketresearch.com/biological-drugs-market.html

Overview of the Global Biological Drugs Market

The global biological drugs market is driven by factors such as the growing prevalence of chronic conditions, increasing geriatric population, and accelerating regulatory compliance. In 2014, the global biological drugs market was worth US$161,056.5 million in 2014. With a 10.1% CAGR expected during the forecast period of 2014 to 2020, the global biological drugs market will reach a market value of US$287,139.7 million by 2020.

By therapeutic protein, the global biological drugs market is segmented into Enbrel, Neulasta, Lantus, Avonex, Rebif, NovoLog, Eylea, Neupogen, Betaseron, Levemir, Epogen, Aranesp, and Humalog. Enbrel is the dominating therapeutic protein sector in the global biological drugs market.

By mAb, the market is divided into Avastin, Rituxan, Remicade, Humira, Herceptin, and Lucentis. According to vaccine, the global biological drugs market is segmented into Ceravix, Varivax, Fluzoone, Gardasil, and Prenvar 13. Humira is the fastest growing mAb sector, while Prevnar 13 is the largest and fastest growing vaccine segment in the global biological drugs market.

In terms of geography, the global biological drugs market is divided into RoW, Europe, Asia, and North America. Presently, North America dominates the market, trailed by Europe due to its increasing adoption and use of biological products for the treatment of cancer, diabetes, and other fatal conditions.

Fill the form for an exclusive sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1694